But can endogenous GLP-1, meaning GLP-1 from-within-the-body, work as an alternative to the drugs that mimic GLP-1, like Ozempic
As the demand for GLP-1s is expected to stir competition in the global pharma CDMO market, CDMOs may look to prioritise lucrative contracts and non-GLP-1 drugs may experience disruption as they struggle to source fill-finish services, primary packaging, and single-use technologies
Curr Drug Deliv 17:651674
Potential off-target effects: broad changes to methylation could, in theory, affect gene expression in ways not yet characterised
Combining CoQ10 and L-carnitine is generally safe and may offer additive benefits, though the evidence for combination protocols is less robust than for individual agents
The gut microbiome contributes to a substantial proportion of the variation in blood lipids